On the basis of retrospective analyses and phase 2 studies, metastatic colorectal cancer patients whose disease responded to a first-line regimen containing an anti-epidermal growth factor receptor (EGFR) agent may experience benefit from anti-EGFR readministration in later therapy lines. While the analysis of circulating tumor DNA seems a promising tool to select the best candidates for this strategy, identifying clinical predictors of anti-EGFR sensitivity would be useful to drive treatment choices in daily practice.

Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis

Germani, Marco Maria;Cremolini, Chiara
2020-01-01

Abstract

On the basis of retrospective analyses and phase 2 studies, metastatic colorectal cancer patients whose disease responded to a first-line regimen containing an anti-epidermal growth factor receptor (EGFR) agent may experience benefit from anti-EGFR readministration in later therapy lines. While the analysis of circulating tumor DNA seems a promising tool to select the best candidates for this strategy, identifying clinical predictors of anti-EGFR sensitivity would be useful to drive treatment choices in daily practice.
2020
Rossini, Daniele; Germani, Marco Maria; Pagani, Filippo; Pellino, Antonio; Dell'Aquila, Emanuela; Bensi, Maria; Liscia, Nicole; Moretto, Roberto; Boccaccino, Alessandra; Prisciandaro, Michele; Manglaviti, Sara; Schirripa, Marta; Vivolo, Raffaella; Scartozzi, Mario; Santini, Daniele; Salvatore, Lisa; Pietrantonio, Filippo; Loupakis, Fotios; Falcone, Alfredo; Cremolini, Chiara
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/1044214
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 19
social impact